Model group (n = 348) | Validation cohort (n = 348) | P value | |
---|---|---|---|
Death [n (%)] | 130 (37.4) | 123 (35.3) | 0.582 |
Survival time (mean ± SD, month) | 28.0 ± 23.7 | 26.6 ± 22.6 | 0.439 |
Age (mean ± SD, year) | 59.5 ± 13.4 | 59.6 ± 13.4 | 0.569 |
Gender (male/female) | 236/112 | 236/112 | 1.0 |
AJCC stage (IV/III/II/I/NA) | 4/80/79/164/21 | 7/70/67/182/22 | 0.226 |
AJCC PT (T4/T3/T2/T1/NA) | 14/74/87/171/2 | 10/71/75/192/0 | 0.163 |
AJCC PN (N3/N2/N1/N0/NA) | 100/3/245/0 | 117/3/228/0 | 0.165 |
AJCC PM (MX/M1/M0/NA) | 96/4/248/0 | 103/7/238/0 | 0.392 |
Radiation treatment adjuvant (yes/no/NA) | 4/130/114 | 5/225/118 | 0.631 |
Pharmaceutical adjuvant (yes/no/NA) | 15/215/118 | 12/213/123 | 0.592 |
Ablation embolization (yes/no/NA) | 13/219/116 | 18/210/120 | 0.328 |